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Summary
Objective: To develop criteria for the selection and application of molecular markers for the study of osteoarthritis (OA).
Methods: Statistical criteria for marker selection for OA are developed.
Results and conclusions: After studying more than 20 different molecular markers for monitoring OA, procedures for choosing markers for
clinical studies have been developed. For a particular study, the process starts with the markers showing ‘face-validity’ for monitoring OA.
They are next required to successfully distinguish OA patients from controls. This necessitates definition of the distribution of marker values
in OA patients and controls. So far, they have been consistently log–normal. The difference (∆) in marker values between OA and controls
defines the opportunity for marker improvement. The between-visit standard deviation (S) in patients puts limits on the detection of marker
changes. The two variables can be combined to estimate the practicality of a marker using a modified power analysis. The number of patients
(N*) required to observe a 50% improvement with an alpha level of P0.05 and with 80% certainty is estimated as 50(S/∆)2. N*, S and ∆
should be used to characterize and compare markers. Marker efficiency can be refined by regressing on secondary variables, such as age,
sex, BMI, severity, etc. Finally, the use of two or more markers may be required to improve marker prediction of clinical outcome. Correlated
markers can be used to reinforce conclusions by essentially adding replicative data. Independent, complementary markers can be used to
develop associations with clinical parameters, and perhaps diagnose and monitor disease status, activities that so far have not been possible
with single markers.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
Key words: Molecular markers, Selection criteria.
Introduction
Improved methods are needed for the monitoring of patient
progression in osteoarthritis (OA) clinical trials. Clinical
measures such as the WOMAC1 and the Lequesne
indices2 reflect pain and disability. They are not the meas-
ures of advancing pathology as determined by changes in
joint structure. Imaging measures, such as radiographs,
MRI and direct visualization by arthroscopy can reflect
advancing pathology, but only when two measurements are
made at sufficiently separated time points, generally 6 to 24
months. Molecular markers offer the potential for improving
clinical assessment3. In principle, markers can be a direct
measure of the rate of disease progression4 and, thus, offer
a quick snapshot of disease activity. However, markers
have so far failed to fulfill this promise in OA3,5–7, and have
only modestly contributed to the evaluation of therapy and
the mechanistic understanding of clinical results.
There are a large number of potential markers for moni-
toring OA4,6–9. Fragments of type II collagen, aggrecan and
COMP have been extensively studied and there are many
additional potentially useful markers. There are FDA guide-
lines10 and detailed criteria11 for the validation of markers.
These criteria address issues such as precision, accuracy,
reproducibility and selectivity. Their purpose is to assure
that an assay provides a valid measurement of a marker’s
concentration. In this article, it is assumed that valid
marker measurements can be made with each assay. We
focus on statistical criteria to choose which markers to use
for clinical monitoring of OA.
Generally, investigators select markers for clinical
studies either because they are considered indicative of
a potential disease mechanism or because they have
the potential to reflect advancing disease pathology.
Lohmander and Felson3 call this ‘face-validity’. Such cri-
teria still leave a large number of molecular markers that
are logical choices for monitoring clinical trials. We
advance criteria for selecting the most appropriate markers
from among many candidates4,6–9 by combining patho-
physiological information with statistical criteria. To date, we
have examined 23 markers in clinical studies (references
12–14 and unpublished studies), and we base our recom-
mendations on this experience.
Face-validity
Criteria of face-validity are largely based on understand-
ing the disease processes. There should be scientific
reason to believe that the level of the marker changes
as the disease activity changes, although this property may
not be certain at the time of marker selection. Of course,
proven utility on clinical application would give the
strongest face justification.
Markers can be classified into several different cate-
gories4: structural markers reflect the turnover of matrix
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components in cartilage, meniscus, subchondral bone and
synovial lining. Loss from the cartilage reflects a change in
the composition of the cartilage matrix and those compo-
sitional changes may be associated with altered structural
properties of the matrix; disease process markers reflect
mechanisms that affect the well-being of the cartilage, e.g.,
IGF1, IL-1, collagenase. Changes in their concentration
may be indicative of processes that can be related to
cartilage breakdown. A direct link to pathology must be
proven, but the changes are worrisome and suggestive of
disease progression; genetic markers reflect increased
likelihood of development of OA or severity of OA, or both,
but they do not indicate current disease activity, and so are
not useful markers of progression; epidemiological markers
reflect factors that may affect the incidence and outcome of
OA, e.g., insulin and estrogen levels, but they, like the
genetic markers, do not measure current disease activity.
Thus, only the first two categories contain potential clinical
markers of disease activity and are candidate markers for
monitoring progression.
Marker distribution
The control and the OA population should each be
characterized by the statistical distribution of their marker
values. It is the distribution of marker values in the two
populations that allows judgments to be made of marker
utility. Some considerations are suggested in the following
discussion.
DEFINING THE OA POPULATION
The first step in any clinical study of markers requires
that the OA population be differentiated from the control
(non-OA) population. Clinical diagnosis depends on struc-
tural criteria (joint space narrowing and osteophyte for-
mation), functional deficits and pain. The importance of
good clinical characterization and classification cannot be
over emphasized since it provides the foundation on which
the criteria for judging the markers is based.
UNITS
Reasonable comparisons between different markers
require that molar rather than mass units be used when-
ever possible. For example, when one mole of collagen α21
chain is degraded into fragments, one mole of each indi-
vidual fragment epitope is typically generated. However, if a
mass unit is utilized, one mole of fragment could range in
size from a few amino acids to hundreds of amino acids,
with as much as a 100-fold difference in mass correspond-
ing to one mole. Similar considerations hold true for other
proteins, such as COMP, link protein, the core protein of
aggrecan, etc. In a few situations, molar units have not
been useful. In the carbohydrate units of aggrecan (chon-
droitin and keratan sulfate), the repetitive structure of the
sugar residues and the effects of aggregation and epitope
distribution require the use a standard preparation.
STATISTICAL DISTRIBUTION
In a typical study, measurements of a vector of marker
values, Xi (ith subject), are obtained at times appropriate to
the study, for a control population and for an OA or a
treated population. To employ standard statistical tools
to determine the significance of differences or of trends,
such as analysis of variance or regression, the sample
values from the control and the OA population should be
distributed approximately normally. However, of the 23
markers we have examined, the values in the OA and
control populations have failed to conform to a normal
probability distribution. Therefore, the first step in an
analysis should be to determine whether the marker is
distributed normally. Normality can be tested statistically by
a Shapiro–Wilk W-test15 and reinforced by visual examin-
ation of a normal probability plot. Both methods are imple-
mented in most standard computer statistical packages. If,
as we have found, the values are not normally distributed,
then depending on the sample size, it is best to either
transform the data to be more nearly normally distributed or
to use non-parametric statistical tests. When the former is
possible, it generally affords more statistical power, and this
is the approach we have taken.
COMPUTATION OF A TRANSFORMED VARIABLE
We have found that reasonable normality can be attained
using a logarithmic transformation. The measured marker
values Xi are transformed into a new variable Ti , where
TilogXi (1)
Now, the average of the transformed values is
TH
I1
N
Ti/N (2)
and the standard deviation S is correspondingly defined in
terms of Ti
SŒ
i1
N
TiTH2/N1 (3)
One must then verify that the Ti’s are close to normally
distributed, as previously suggested.
UNDERSTANDING THE DISTRIBUTION OF MARKER VALUES
A normal distribution is characterized by its mean and
standard deviation, but the values are not so easily under-
stood when a log–normal distribution is used. Therefore,
after statistical tests, such as analysis of variance have
been conducted, statistical values should be back-
transformed to original units so that the results can be
readily understood. By back-transforming the mean TH, the
geometric mean is obtained:
XHg10T1I1
N
Xi21/N (4)
Similar to the mean Xi, the standard deviation S of the Ti
can be back-transformed. Defining
R10S (5)
R gives the bounds of the population. In a normally
distributed sample, 1 standard deviation above and below
the sample mean THS includes approximately 66% of the
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population. Now, because of the properties of logarithms,
the lower bound is the ratio XHg/R and the upper bound is
the product XHg*/R. Instead of TH±S, we correspondingly
write XHg*R, which means that it must be multiplied and
divided by R to get the confidence bounds. Again, XHg*/R
contains 66%, and XHg*/2R contains 95% of the population(2 standard deviations), corresponding to a 95% confi-
dence interval for XHg.
A marker must differentiate the OA population
from the non-arthritic controls
If a marker cannot readily distinguish OA patients from
controls, then there is nothing to measure in cross-
sectional studies16. If it can distinguish OA patients from
controls, then statistics can be used to define its practical
application through a power test.
SENSITIVITY AND SPECIFICITY
Generally, the two terms sensitivity and specificity have
been used to characterize the ability of a marker to classify
patients and controls into the proper category. Given that a
subject is an OA patient, sensitivity is the conditional
probability that the marker in question will classify the OA
patient as an OA patient and not as a control17. Because
OA is typically somewhat advanced before it is diagnosed,
i.e., OA is diagnosed only after clinical recognition of joint
space narrowing, osteophyte formation and pain; marker
sensitivity is typically quite high. Specificity is the con-
ditional probability that a marker will properly classify a
control subject as a control. The most useful markers are
expected to lack specificity because their elevation should
antedate the clinical diagnosis of OA. Of course, pros-
pective studies will be necessary to determine whether the
marker elevation in controls identifies pre-clinical OA.
DIFFERENCE IN MARKER LEVELS BETWEEN CONTROLS AND OA
PATIENTS
The difference in marker levels between controls and OA
patients gives the window of opportunity for meaningful
contrasts. This can be determined from cross-sectional
data. For the 23 markers we examined, the distribution of
logarithms of the marker values, but not the untransformed
values, are approximately normally distributed. Standard
analysis of variance with F-test or Student’s t-test can be
used to determine statistical significance of differences
between OA and control populations. A significant differ-
ence between the OA and control populations suggests,
but does not guarantee a good marker. If there is a
statistical difference between the two populations, it be-
comes appropriate to consider the difference ∆
∆XHOAXHControl (6)
between the geometric means of the OA and control
populations. The difference indicates the opportunity for
improvement of the marker.
The variance between clinical visits
The design of clinical studies is based on the ability to
detect change over time in individual patients. The sensi-
tivity for the detection of change is determined by the
standard deviation of sequential measurements in an indi-
vidual patient. In most marker studies, only a cross-
sectional standard deviation is determined. While this is
useful to demonstrate that a difference exists between the
patient and the control population, it fails to define the
potential usefulness of the marker for monitoring clinical
studies.
The limiting statistic for clinical studies is the standard
deviation of the marker levels between the patient visits in
stable patients. This standard deviation (S) is much larger
than the validation standard deviation, i.e., the precision,
accuracy and reproducibility between the independent
measurements of the same sample. We found that S
measured as the coefficient of variation (S/mean) between
four and five patient visits rises to over 25% for some
markers. Lohmander et al.18 found similar variability. This S
is much higher than the standard deviation between the
independent replicates (3–6%) run on different days and
the independent replicates on the same day (1–3%). Unlike
the cross-sectional standard deviation, it generally con-
forms to a normal distribution. It is the between-visit error
that limits the utility of most markers, since to be useful for
diagnostic or prognostic clinical use, the marker differences
for discrimination should exceed the between-visit error.
Power analysis determines practical clinical
utility
With many markers fulfilling the ‘face-validity’ criteria, it is
important to have additional criteria to judge how practical a
marker will be in the clinic. It is suggested that the following
power analysis formula19 be used as a routine criterion
marker practicality:
N*50(S/∆)2 (7)
N* is the number of patients in a treatment OA group
required to see a statistically significant change in which
the OA group marker values are moved toward controls
by 50%, i.e., a change of ∆/2. It is computed from ∆
XHOAXHControl, the difference between the geometric mean
values of OA and control populations and S, the between-
visit standard deviation in stable OA patients. N* gives a
single number for comparison of markers. By estimating
the number of patients required to detect a substantial shift
in marker levels towards controls, N* indicates marker
practicability.
N* power analysis reflects the standard method of ana-
lyzing clinical trials. A statistically significant change from
the patient pre-treatment values is sought. To assure that
the change might be large enough to reflect a meaningful
clinical change, our power calculation is based on a 50%
shift in marker value toward controls. While it is possible
that smaller or larger changes might be necessary for
clinical significance, this gives a reasonably robust
standard and avoids the problem of seeking statistical
significance with a minor change in marker levels.
∆ and S are also important parts of the characterization
of markers. For comparisons, ∆ and S are best expressed
after division by XHOA to give a coefficient of change, ∆/XHOA,
and a coefficient of variation, S/XHOA.
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The OA population
Almost all clinical studies using markers have been
based on use of a categorical classification of OA (OA yes
or no). We suspect that the patient population is typically
selected from more severe cases since they are generally
taken from university centers. This may lead to an over-
estimate of the discriminatory capacity of a marker. This
problem has been previously discussed20. Unfortunately,
the relationship of marker levels to disease severity or to
other clinical parameters is simply unknown. Are marker
levels related to the number of affected joints, the volume of
the affected joints, the extent of disease damage or the rate
of disease progression? How readily can a marker pick up
early, pre-OA changes? These relationships are undefined
for every marker. This could be corrected by comparing
clinical measurements with marker levels rather than just
categorical OA. However, such data are not currently
available, so power analysis must be based on categorical
OA at this time.
Clinical trials of therapeutic intervention
The selection of a marker may also be dictated by the
aims of the clinical study. Where a therapeutic agent has a
specific mechanism of action, a particular marker may best
reflect the activity of the agent. However, that marker may
be different from one that best reflects the clinical response
to the intervention. Collagenase inhibitors offer one
example. A collagenase neoepitope antibody14,21 may be
quite appropriate for pharmacodynamics measurements,
whereas measurement of the type II collagen cross-
link22,23 might better estimate total collagen breakdown.
Thus, monitoring of different markers may be required to
reflect the mechanistic and the clinical effectiveness of the
intervention.
Correlation with structural change
Ideally, a marker associated with the rate of OA disease
progression is sought. Correlation between marker elev-
ation and structural change derived from X-ray or MRI may
be strengthened if other potentially confounding variables
(age, sex, menopausal status, BMI, severity, etc.) can be
taken into account. These effects can be determined and
compensated for by tools such as multiple logistic regres-
sion or composite predictors derived by factor analysis.
However, criteria such as N* will tell whether it is worthwhile
to proceed to collect the clinical data to associate with
the marker. If the power calculations give extremely high
patient numbers, it is best to go back to the drawing board
and figure out how to improve the marker’s measurement
characteristics before undertaking expensive clinical trials.
Because only serum or urinary markers are suitable for
routine use, the differentiation between controls and OA
patients will remain far less clear-cut than can be achieved
with measurements made in synovial fluid24. Thus, it may
be advantageous to strengthen the correlation by using
complementary dependent markers13 and/or independent
markers12,25. While ideally, the addition of other markers
should add to the discriminatory power of the study, it
is important to use power analysis to ensure that any
additional marker adds value, and not just cost, to the
clinical analysis.
Some examples
The literature has a paucity of data using the log trans-
formed analysis method advocated herein. Even when
used, the values for the transformed means and standard
deviations are rarely given, so that power calculations can
be made from them.
USE OF POWER ANALYSIS TO SUGGEST SAMPLE SIZE
For the cartilage oligomeric protein (COMP), we found a
coefficient of difference of 16% between the OA and the
control population13, and a between-visit coefficient of
variance around 14%. For OA patients, the distribution can
be characterized by 8.7*/1.14 µM. Power analysis to detect
a 50% change requires about 27 patients.
For TIINE, the collagenase-generated neoepitope frag-
ment of type II collagen14, the difference between the
geometric means of the control and OA population is about
two-fold, i.e., a coefficient of difference of 45% and the
between-visit coefficient of variance is around 23%. The
distribution in OA patients can be characterized by the
back-transformed values 1.8*/1.23 nM. Power analysis to
detect a 50% change requires about 13 patients. If instead,
the difference between young controls (coefficient of differ-
ence of 75%), rather than age-matched controls, is used,
the power analysis gives five patients. The difference
between the patient number calculated for COMP and
TIINE arises from the greater spread between the control
and OA populations.
THE USE OF POWER ANALYSIS TO SELECT A STUDY PATIENT
POPULATION
One extensive study on COMP [26] has provided log
transformed numbers including the difference between
control and OA patients, and segregated the patients
according to the involvement of one or more large joints
(Table I). Although they did not provide an estimate of
between-visit error for COMP, we assume that the
between-visit error is similar to our COMP data of 14%. In
the case of clinical studies carried out on patients with
involvement of one large joint, the coefficient of difference
between COMP values (the data are taken directly from
their Table 4 and back-transformed to geometric means) for
control and OA patients is 2% compared to those with
involvement of two (difference16%) or three or four
(difference23%) large joints. These numbers allow one to
calculate that it will take about 70 times more patients to be
able to reach a 50% improvement, if there was involvement
of only one large joint vs two (2500 patients vs 36 patients).
The results illustrate the practical utility of the power
calculation criteria. By focusing on patients with involve-
ment of two or more large joints, the numbers of patients
are manageable and COMP is a good candidate marker
for studying the clinical effects. A similar requirement for
multiple joint involvement is apparent in the data of Atley
et al.22 using the type II collagen CTX marker.
THE USE OF MULTIPLE MARKERS
Garnero et al.25 have explored the use of two markers to
improve the correlation with X-ray progression and arthro-
scopic progression of OA. Using a Z-score27 for the type II
collagen cross-link (CTX-II) and for type II collagen synthe-
sis as measured by the C-propeptide of type II collagen
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(PIIANP), they found a much stronger relationship to pro-
gression for the combined Z-score than with the Z-score of
either marker alone.
Conclusions
We have presented criteria for making comparisons
between markers and for selection of markers for clinical
use. Generally markers are chosen because of their poten-
tial to reflect disease progression. Our criteria are based on
the difference in marker values between the control and
the OA populations. When combined with the between-
visit standard deviation, this permits the estimation of the
patient numbers required to make a meaningful discrimi-
nation of change. The patient number criterion (N*) should
permit more quantitative judgments to be made about the
practicality of individual markers for use in clinical trials.
Use of such criteria can help in selecting the best marker
and the best patient population for study. Once clinical
studies have been carried out, the practicality of a marker
as a disease measure can be refined by logistic regression
and/or factor analysis. At this early stage of OA marker
development, two or more markers may need to be used in
tandem to get a strong clinical correlation with reasonable
numbers of patients.
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